BLOOD COUNT-DERIVED INFLAMMATORY BIOMARKERS AND NEUROCOGNITIVE PERFORMANCE IN RELAPSING REMITTING MULTIPLE SCLEROSIS: A PROSPECTIVE PILOT STUDY
National Autonomous University of Mexico
Presentation
Date TBA
Event Information
Poster Board
PS03-08AM-008
Poster
View posterAbstract
Relapsing–remitting multiple sclerosis (RRMS) is a chronic neuroinflammatory disease characterized by immune dysregulation and neurological impairment. Peripheral inflammatory indices derived from routine blood counts have emerged as accessible biomarkers, yet their clinical relevance in RRMS remains incompletely defined. We evaluated blood count–derived inflammatory indices and their association with systemic inflammation and neurocognitive and functional performance in RRMS patients before and after methylprednisolone treatment.
This exploratory pilot study included RRMS patients during relapse (T0) and after treatment (T1), as well as age- and sex-matched healthy controls. Inflammatory indices (NLR, MLR, PLR, SIRI, SII, AISI, CLR and CAR) and serum C-reactive protein (CRP) were assessed. Disability and cognition were evaluated using the EDSS scale and the MoCA test. Group comparisons, correlation analyses, receiver operating characteristic (ROC) curves, t-distributed stochastic neighbor embedding (t-SNE), Random Forest classification and Boolean modeling were performed.
At baseline, RRMS patients showed significantly elevated NLR, MLR, SIRI, SII, AISI, CLR and CAR compared with controls. Several indices remained abnormal after treatment, indicating persistent systemic inflammation. SII correlated with CRP and EDSS after treatment. ROC analysis identified MLR, SIRI and AISI as the most accurate discriminators of RRMS (AUC 0.83–0.92). Random Forest analysis highlighted SIRI and AISI as the most influential predictors. Boolean modeling yielded a simple rule (SIRI > 0.62) achieving 92% accuracy.
Peripheral inflammatory indices, particularly SIRI, MLR and AISI, are altered during RRMS relapse and retain discriminatory value after corticosteroid therapy. These low-cost biomarkers may support clinical monitoring and future risk stratification in RRMS.
Recommended posters
INVESTIGATION OF THE PREDICTABILITY OF DIAGNOSTIC STABILITY AND DISEASE COURSE IN FIRST-EPISODE PSYCHOSIS USING BRAIN MORPHOLOGY AND PERIPHERAL INFLAMMATORY MARKERS
Kübra Dikici Saraçoğlu, Muhammed Balli, Simge Seren Kirlioglu Balcioglu, Hale Yapici Eser
REGULATORY NEUTROPHILS IN MULTIPLE SCLEROSIS AND THEIR ROLE IN IMMUNOSURVEILLANCE
Alessia Bottoni, Susanna Manenti, Annamaria Finardi, Alessandra Mandelli, Edoardo Pedrini, Smyth Leon C. D., Kipnis Jonathan, Roberto Furlan
D-SERINE REFLECTS INTRATHECAL INFLAMMATION IN MULTIPLE SCLEROSIS AND COUNTERACTS MOTOR IMPAIRMENT IN A MURINE MODEL
Alessandro Usiello, Kenta Arisumi, Tommaso Nuzzo, Luana Gilio, Sakiko Taniguchi, Rosita Russo, Haruhiko Motegi, Raffaella di Vito, Junichi Hata, Francesco Errico, Akinori Hashiguchi, Hideyuki Okano, Roberto Furlan, Annamaria Finardi, Mario Stampanoni Bassi, Jin Nakahara, Masashi Mita, Takanori Kanai, Angela Chambery, Masato Yasui, Diego Centonze, Jumpei Sasabe
MULTIMODAL MRI AND METABOLOMICS REVEAL NEUROPROTECTIVE EFFECTS OF NLRP3 INFLAMMASOME INHIBITION IN A PROGRESSIVE MOUSE MODEL OF MULTIPLE SCLEROSIS
Nemat Khan, Abdullah Althobity, Vinod Kumar, Gary Cowin, Ian Brereton, Nyoman Kurniawan, Trent Woodruff
TRACKING PERIPHERAL IMMUNE CELL PROFILES ALONG ALS PROGRESSION AT SINGLE-CELL RESOLUTION
Esther Alvarez, Álvaro Carbayo, Natalia Valle-Tamayo, Laia Muñoz, Joaquim Aumatell, Soraya Torres, Sara Rubio-Guerra, Jesús García-Castro, Judit Selma-González, Daniel Alcolea, Janina Turon-Sans, Alberto Lleó, Ignacio Illán-Gala, Juan Fortea, Ricard Rojas-García, Oriol Dols-Icardo
A NOVEL BIOSIGNATURE OF BIPOLAR DISORDER IDENTIFIES SUBJECTS DURING BOTH AFFECTIVE EPISODES AND EUTHYMIA: ROLE OF THE SYSTEMIC‑INFLAMMATORY (SII) INDEX AND OF GENDER DIFFERENCES
Alessandra Berry, Letizia Giona, Barbara Collacchi, Francesca Cirulli, Matteo Di Vincenzo, Elena Piegari, Chiara Del Giorno, Mario Luciano, Andrea Fiorillo